Parkinson's drug safety trial halted early
Symptom relief
Terminated
This early-stage study tested the safety of an intravenous drug called talineuren in 22 people with Parkinson's disease. Talineuren is a form of GM1, a natural substance, given as an add-on to their usual treatment. The study was stopped early, and its main goal was to check for …
Phase: PHASE1 • Sponsor: InnoMedica Schweiz AG • Aim: Symptom relief
Last updated May 04, 2026 16:21 UTC